A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
Фаза 2
Завершено
NCT04535544
| Заболевание | Hepatitis D, Chronic |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Janssen Research & Development, LLC |
|---|
| Статус | Завершено |
|---|
| Участники | 52 участн. |
|---|
| Вмешательство | JNJ-73763989, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF) |
|---|
| Дата начала | 17.09.2020 |
|---|
| Дата завершения | 19.10.2023 |
|---|
| Публикация результатов | 6.11.2024 |
|---|
Кратко
The purpose of the study is to evaluate on-treatment efficacy against hepatitis D virus (HDV) of JNJ-73763989 + nucleos(t)ide analog (NA) regimen compared to NA alone.
Double-blind:Part 1: Percentage of Participants With HDV Ribonucleic Acid (RNA) >=2 log10 IU/mL Decline From Baseline or HDV RNA Target Not Detected (TND) in Combination With Normal Alanine Aminotransferase (ALT) at Week 48 (Multiple Imputation Approach)
Week 48 · Percentage of Participants
| Part 1: JNJ-73763989 (JNJ-3989) + Nucleos(t)Ide Analog (NA) | 33.3 Percentage of Participants |
|---|
| Part 1: Placebo + NA | 0.0 Percentage of Participants |
|---|
Double-blind: Part 2: Percentage of Participants With HDV RNA >=2 log10 IU/mL Decline From Baseline or HDV RNA TND in Combination With Normal ALT at Week 48 (Multiple Imputation Approach)
Week 48 · Percentage of Participants
| Part 2: JNJ-73763989 (JNJ-3989) + NA | 30.0 Percentage of Participants |
|---|
| Part 2: Placebo + NA | 0.0 Percentage of Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.